TD is caused by prolonged exposure to medications that block dopamine receptors, including antipsychotic drugs and some drugs used to treat nausea.
The company said that dopamine is a chemical that communicates between certain nerve cells in the brain.
This disorder is characterized by involuntary, repetitive movements that usually involve the face and in more severe cases affect the trunk and/or extremities.
AOP Orphan CEO and founder Dr Rudolf Widmann said: "The opportunity to bring relief to the many patients who face the debilitating effects of movement disorders and suffer from the effects of conditions such as tardive dyskinesia is greatly needed and humbling."
AOP Orphan board member and Business Development director Georg Fischer said: "People living with movement disorders and those around them often need support and services beyond medication.
"We have the infrastructure, existing strong relationships with neurologists, therapeutic expertise in CNS and passion in place to assist them."
Tetrabenazine is marketed in countries including Austria, Denmark, France, Germany, Ireland, Portugal, the UK, as well as in several Central Eastern European territories.
The drug is approved for treatment of chorea associated with Huntington’s disease (HD), a rare inherited neurological disorder, which results from genetically programmed degeneration of brain cells.